Addex Starts A Second Phase IIb Trial Of ADX10059 In GERD

Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced the start of a Phase IIb trial of ADX10059 monotherapy in patients with gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms. ADX10059 is a first-in- class reflux inhibitor that works by reducing activation of the metabotropic glutamate receptor 5 (mGluR5) through negative allosteric modulation (NAM).

More: continued here

Filed under: Acid Reflux/GERD on December 20th, 2008